News

Halozyme's OCREVUS ZUNOVO™: A Breakthrough in MS Treatment

Halozyme's OCREVUS ZUNOVO™: A Breakthrough in MS Treatment

Halozyme's Latest Innovation: OCREVUS ZUNOVO™ Approved

The recent FDA approval of OCREVUS ZUNOVO™, created by Roche using Halozyme's ENHANZE® drug delivery technology, marks a major step forward in treating relapsing and primary progressive multiple sclerosis (MS). This new formulation offers a simpler subcutaneous injection method, making it easier for patients who might struggle with the limitations of intravenous (IV) infusions to access treatment.

What This Approval Means for Patients

For people living with MS, OCREVUS ZUNOVO™ offers an essential treatment option. Healthcare providers can now deliver the medication in about 10 minutes, a significant improvement over traditional delivery methods. This switch to subcutaneous administration is especially beneficial for patients in facilities lacking IV capabilities. Dr. Helen Torley, president and CEO of Halozyme, expressed pride in this milestone, highlighting that this new formulation enhances flexibility in treatment and improves the patient experience overall.

Evidence Supporting OCREVUS ZUNOVO™

This approval is backed by encouraging results from the Phase III OCARINA II trial. This important study confirmed that the subcutaneous delivery of OCREVUS ZUNOVO™ maintains drug levels similar to those of the intravenous version and has a comparable safety profile. The trial results showed promising reductions in relapse activity and MRI lesions among a significant number of participants, which are crucial indicators for evaluating MS treatments.

Patient Satisfaction and Safety

Furthermore, more than 92% of participants in the trial expressed satisfaction with the subcutaneous method of administering OCREVUS ZUNOVO™, suggesting a strong positive response to this delivery approach. Importantly, the safety profile of OCREVUS ZUNOVO™ closely mirrors that of existing treatments, with the most common adverse events being mild to moderate injection reactions that did not lead to patients discontinuing therapy.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. was founded to improve patient experiences and is recognized for its pioneering ENHANZE® drug delivery technology. This technology facilitates the subcutaneous administration of medications, aiming to lessen the burden of treatment for patients. With a presence in over 100 global markets and a positive impact on more than 800,000 patients, Halozyme collaborates with major industry leaders, including Roche, Takeda, and AbbVie.

Future Developments and Collaborations

Beyond its innovative drug delivery solutions, Halozyme is focused on developing drug-device combination products that enhance convenience and ensure patient compliance. This aligns with ongoing efforts to transform MS treatment and expand into other therapeutic areas. Halozyme's commercial proprietary products, Hylenex® and XYOSTED®, as well as collaborative efforts with Teva and Idorsia Pharmaceuticals, illustrate the company's dedication to advancing healthcare solutions.

Halozyme's Commitment to Innovation

Located in San Diego, CA, Halozyme demonstrates its commitment to blending technology with healthcare to meet unmet patient needs. With continuous advancements in drug delivery technologies, Halozyme is well-positioned to expand its influence within the biopharmaceutical sector, consistently prioritizing the improvement of patient care.

Frequently Asked Questions

What is OCREVUS ZUNOVO™?

OCREVUS ZUNOVO™ is a newly approved formulation of ocrelizumab for subcutaneous use, targeting relapsing and primary progressive MS.

How does the subcutaneous administration compare to intravenous delivery?

Subcutaneous administration is faster, taking around 10 minutes, and it's more convenient for facilities without IV capabilities.

What were the results of the clinical trials for OCREVUS ZUNOVO™?

The trials showed that drug levels remained non-inferior and safety profiles were similar to the IV formulation, with high levels of patient satisfaction.

Who is Halozyme Therapeutics?

Halozyme Therapeutics, Inc. is a biopharmaceutical company recognized for its ENHANZE® drug delivery technology, focusing on innovative therapies that enhance patient experiences.

What are the future prospects for Halozyme?

Halozyme aims to grow its drug delivery solutions and build partnerships that will broaden treatment options across various therapeutic fields.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 119

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 23

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 119

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 62

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 26

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 103

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 20

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 75

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 108

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Green Lumber Recall Raises a Serious Safety Question

Updated Category News Views 41

A blister-pack code is doing far more work than it ever should. Green Lumber Holdings is recalling Green Lumber Natural Fuel For Men, lot GL01 with expiration 09/27, after FDA laboratory analysis confirmed undeclared tadalafil in additional samples. The company says the consumer-level recall begins November 19, 2026. This is not a cute labeling nitpick or a marketing...

Continue Reading

Top 5 Most Recently Viewed Articles

Harnessing AI for a Transformative Future in Human Resources

Updated Category News Views 193

The Impact of AI on Human Resources in 2026 As we look towards the future of work in 2026, the influence of artificial intelligence (AI) on human resources (HR) is undeniable. Businesses worldwide are adapting to an ecosystem increasingly shaped by AI, which plays a critical role in improving workforce efficiency. With insights from industry experts at ADP, organizations...

Continue Reading
Collins Aerospace Expands Executive Aircraft Seating Operations

Updated Category News Views 110

Collins Aerospace Expands Executive Aircraft Seating Operations Doubled production floor space and new machinery improves capacity and customization opportunities Collins Aerospace, a business unit of RTX (NYSE: RTX), is enhancing its executive aircraft seating facility with a significant $2 million investment. This expansion doubles the upholstery production floor space...

Continue Reading
Celebrating Success: Beyond Finance's Commitment to Clients

Updated Category News Views 345

Beyond Finance's Recognition for Outstanding Customer Service Beyond Finance, a leading name in the debt consolidation sector, proudly received the 2025 Excellence in Customer Service Award from the Business Intelligence Group. This accolade highlights the organization's unwavering commitment to transforming the lives of its clients by providing exceptional onboarding and...

Continue Reading
Understanding Bitcoin's Recent Price Fluctuations and Trends

Updated Category News Views 387

Bitcoin Faces Recent Price Challenges Bitcoin has experienced a 6% drop over the past month; nonetheless, it continues to be in a macro bull market. This resilience makes it outperform many other investment options as the cryptocurrency world evolves. What To Make of Recent Market Trends? Understanding Market Dynamics Notable crypto analyst Ali Martinez has pointed out...

Continue Reading
Chudnovsky Law Welcomes Brian D. Bill as New License Defense Attorney

Updated Category News Views 151

Chudnovsky Law's New Addition: Brian D. Bill Brian D. Bill has recently joined Chudnovsky Law, a distinguished law firm specializing in professional license defense. With California housing over 4.3 million licensed professionals, the need for expert defense in license investigations and enforcement cases is crucial. Brian D. Bill's Legal Background Mr. Bill brings...

Continue Reading